Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major lipodystrophy markets are expected to exhibit a CAGR of 4.45% during 2024-2034.
The lipodystrophy market has been comprehensively analyzed in IMARC's new report titled "Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lipodystrophy is a rare metabolic disorder characterized by abnormal fat distribution or the loss of body fat. Individuals suffering from the ailment may have excess fat in some areas, such as the neck and abdomen, and a lack of fat in other places, including the arms, legs, face, etc. The condition is often associated with metabolic complications, such as insulin resistance, diabetes, fatty liver, high levels of triglycerides in the blood, etc. Various other symptoms of lipodystrophy are muscle hypertrophy, acanthosis nigricans (dark, thickened skin), an enlarged liver or spleen, etc. The diagnosis of the ailment typically involves a combination of clinical evaluation, imaging procedures, and laboratory tests. Healthcare providers may also assess the distribution of body fat and the presence of metabolic complications, such as insulin resistance and diabetes. Numerous imaging procedures, including ultrasound and MRI, can provide information about body composition as well as fat distribution. Additionally, blood tests are also utilized to evaluate glucose and lipid levels in the patients.
The increasing cases of mutations in genes that regulate adipose tissue development and control metabolism are primarily driving the lipodystrophy market. Besides this, the widespread adoption of insulin sensitizers, such as metformin and pioglitazone, to improve glucose control as well as reduce the risk of diabetes in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of leptin replacement therapy in patients with generalized lipodystrophy, who have low levels of the hormone leptin, is also bolstering the market growth. This therapy helps to regulate metabolism and improves lipid levels as well as insulin sensitivity. Additionally, several key players are exploring the use of GLP-1 agonists to reduce blood sugar levels and lower the risk of cardiovascular diseases in indiviuals with lipodystrophy. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of numerous advanced imaging tests, such as DEXA scans, which provide a visual representation of body fat distribution and information regarding metabolic abnormalities that can aid in the accurate diagnosis and better management of the disorder, is expected to drive the lipodystrophy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the lipodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lipodystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lipodystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lipodystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lipodystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lipodystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lipodystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lipodystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lipodystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of lipodystrophy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with lipodystrophy across the seven major markets?
What is the size of the lipodystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lipodystrophy?
What will be the growth rate of patients across the seven major markets?
Lipodystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lipodystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lipodystrophy market?
What are the key regulatory events related to the lipodystrophy market?
What is the structure of clinical trial landscape by status related to the lipodystrophy market?
What is the structure of clinical trial landscape by phase related to the lipodystrophy market?
What is the structure of clinical trial landscape by route of administration related to the lipodystrophy market?
The lipodystrophy market has been comprehensively analyzed in IMARC's new report titled "Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lipodystrophy is a rare metabolic disorder characterized by abnormal fat distribution or the loss of body fat. Individuals suffering from the ailment may have excess fat in some areas, such as the neck and abdomen, and a lack of fat in other places, including the arms, legs, face, etc. The condition is often associated with metabolic complications, such as insulin resistance, diabetes, fatty liver, high levels of triglycerides in the blood, etc. Various other symptoms of lipodystrophy are muscle hypertrophy, acanthosis nigricans (dark, thickened skin), an enlarged liver or spleen, etc. The diagnosis of the ailment typically involves a combination of clinical evaluation, imaging procedures, and laboratory tests. Healthcare providers may also assess the distribution of body fat and the presence of metabolic complications, such as insulin resistance and diabetes. Numerous imaging procedures, including ultrasound and MRI, can provide information about body composition as well as fat distribution. Additionally, blood tests are also utilized to evaluate glucose and lipid levels in the patients.
The increasing cases of mutations in genes that regulate adipose tissue development and control metabolism are primarily driving the lipodystrophy market. Besides this, the widespread adoption of insulin sensitizers, such as metformin and pioglitazone, to improve glucose control as well as reduce the risk of diabetes in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of leptin replacement therapy in patients with generalized lipodystrophy, who have low levels of the hormone leptin, is also bolstering the market growth. This therapy helps to regulate metabolism and improves lipid levels as well as insulin sensitivity. Additionally, several key players are exploring the use of GLP-1 agonists to reduce blood sugar levels and lower the risk of cardiovascular diseases in indiviuals with lipodystrophy. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of numerous advanced imaging tests, such as DEXA scans, which provide a visual representation of body fat distribution and information regarding metabolic abnormalities that can aid in the accurate diagnosis and better management of the disorder, is expected to drive the lipodystrophy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the lipodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lipodystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lipodystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lipodystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lipodystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lipodystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lipodystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lipodystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lipodystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of lipodystrophy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of lipodystrophy by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with lipodystrophy across the seven major markets?
What is the size of the lipodystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lipodystrophy?
What will be the growth rate of patients across the seven major markets?
Lipodystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lipodystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lipodystrophy market?
What are the key regulatory events related to the lipodystrophy market?
What is the structure of clinical trial landscape by status related to the lipodystrophy market?
What is the structure of clinical trial landscape by phase related to the lipodystrophy market?
What is the structure of clinical trial landscape by route of administration related to the lipodystrophy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LIPODYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LIPODYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LIPODYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 LIPODYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LIPODYSTROPHY - UNMET NEEDS
10 LIPODYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 LIPODYSTROPHY - MARKETED PRODUCTS
11.1 List of Lipodystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Myalept (Metreleptin) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Egrifta (Tesamorelin) - Theratechnologies
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LIPODYSTROPHY - PIPELINE DRUGS
12.1 List of Lipodystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 REGN4461 - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AKCEA-ANGPTL3-LRx - Ionis Pharmaceuticals/Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LIPODYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LIPODYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LIPODYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lipodystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lipodystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lipodystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lipodystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lipodystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lipodystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lipodystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lipodystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lipodystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lipodystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lipodystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lipodystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lipodystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lipodystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lipodystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lipodystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lipodystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lipodystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lipodystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lipodystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lipodystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lipodystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lipodystrophy - Access and Reimbursement Overview
16 LIPODYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LIPODYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LIPODYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LIPODYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LIPODYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LIPODYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 LIPODYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LIPODYSTROPHY - UNMET NEEDS
10 LIPODYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 LIPODYSTROPHY - MARKETED PRODUCTS
11.1 List of Lipodystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Myalept (Metreleptin) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Egrifta (Tesamorelin) - Theratechnologies
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LIPODYSTROPHY - PIPELINE DRUGS
12.1 List of Lipodystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 REGN4461 - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AKCEA-ANGPTL3-LRx - Ionis Pharmaceuticals/Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LIPODYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LIPODYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LIPODYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lipodystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lipodystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lipodystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lipodystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lipodystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lipodystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lipodystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lipodystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lipodystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lipodystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lipodystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lipodystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lipodystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lipodystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lipodystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lipodystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lipodystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lipodystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lipodystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lipodystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lipodystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lipodystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lipodystrophy - Access and Reimbursement Overview
16 LIPODYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LIPODYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LIPODYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
